<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37429672</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2053-8790</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Lupus science &amp; medicine</Title><ISOAbbreviation>Lupus Sci Med</ISOAbbreviation></Journal><ArticleTitle>Protocol for virtual physical examination in an observational, longitudinal study evaluating virtual outcome measures in SLE.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e000952</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/lupus-2023-000952</ELocationID><Abstract><AbstractText Label="OBJECTIVE">There is a lack of data on the use of telemedicine (TM) in SLE. SLE outcome measures remain complex, and clinicians and clinical trialists have raised concerns about the accuracy of virtual disease activity measures. This study evaluates the level of agreement between virtual SLE outcome measures and face-to-face (F2F) encounter. Here, we describe the study design, virtual physical examination protocol and demographics for the first 50 patients evaluated.</AbstractText><AbstractText Label="METHODS AND ANALYSIS">This is an observational, longitudinal study of 200 patients with SLE with varying levels of disease activity from 4 academic lupus centres serving diverse populations. Each study participant will be evaluated at a baseline and a follow-up visit. At each visit, participants are evaluated by the same physician first via a videoconference-based TM and then a F2F encounter. For this protocol, virtual physical examination guidelines relying on physician-directed patient self-examination were established. SLE disease activity measures will be completed immediately after the TM encounter and repeated after the F2F encounter for each visit. The degree of agreement between TM and F2F disease activity measures will be analysed using the Bland-Altman method. An interim analysis is planned after the enrolment of the first 50 participants.</AbstractText><AbstractText Label="ETHICS AND DISSEMINATION">This study has been reviewed by the Columbia University Medical Center Institutional Review Board (IRB Protocol #: AAAT6574). The full results of this study will be published after the final data analysis of 200 patients. The abrupt shift to TM visits due to the COVID-19 pandemic disrupted clinical practice and clinical trials. Establishing a high level of agreement between SLE disease activity measures obtained with videoconference TM and F2F at the same time point, will allow for improved assessment of disease activity when F2F data cannot be acquired. This information may guide both medical decision-making and provide reliable outcome measures for clinical research.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Askanase</LastName><ForeName>Anca D</ForeName><Initials>AD</Initials><Identifier Source="ORCID">0000-0003-4597-5023</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Columbia University Irving Medical Center, New York City, New York, USA ada20@cumc.columbia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aranow</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-9299-0053</Identifier><AffiliationInfo><Affiliation>The Center for Autoimmune &amp; Musculoskeletal Disease, The Feinstein Institute for Medical Research, Manhasset, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Mimi Y</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>Department of Epidemiology &amp; Population Health Division of Biostatistics, Albert Einstein College of Medicine, Bronx, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamen</LastName><ForeName>Diane L</ForeName><Initials>DL</Initials><Identifier Source="ORCID">0000-0002-7698-980X</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arriens</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-9546-1664</Identifier><AffiliationInfo><Affiliation>Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khalili</LastName><ForeName>Leila</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-1070-0997</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Columbia University Irving Medical Center, New York City, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-6599-980X</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Columbia University Irving Medical Center, New York City, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barasch</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Columbia University Irving Medical Center, New York City, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dall'Era</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, UCSF, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mackay</LastName><ForeName>Meggan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The Center for Autoimmune &amp; Musculoskeletal Disease, The Feinstein Institute for Medical Research, Manhasset, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus Sci Med</MedlineTA><NlmUniqueID>101633705</NlmUniqueID><ISSNLinking>2053-8790</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010808" MajorTopicYN="N">Physical Examination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">lupus erythematosus, systemic</Keyword><Keyword MajorTopicYN="N">outcome assessment, health care</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>11</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>10</Day><Hour>21</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37429672</ArticleId><ArticleId IdType="pmc">PMC10335468</ArticleId><ArticleId IdType="doi">10.1136/lupus-2023-000952</ArticleId><ArticleId IdType="pii">10/2/e000952</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008;358:929&#x2013;39. 10.1056/NEJMra071297</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra071297</ArticleId><ArticleId IdType="pubmed">18305268</ArticleId></ArticleIdList></Reference><Reference><Citation>Slawsky KA, Fernandes AW, Fusfeld L, et al. . A structured literature review of the direct costs of adult systemic lupus erythematosus in the US. Arthritis Care Res 2011;63:1224&#x2013;32. 10.1002/acr.20502</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.20502</ArticleId><ArticleId IdType="pubmed">21584945</ArticleId></ArticleIdList></Reference><Reference><Citation>Yelin E, Trupin L, Katz P, et al. . Work dynamics among persons with systemic lupus erythematosus. Arthritis Rheum 2007;57:56&#x2013;63. 10.1002/art.22481</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22481</ArticleId><ArticleId IdType="pmc">PMC2875125</ArticleId><ArticleId IdType="pubmed">17266065</ArticleId></ArticleIdList></Reference><Reference><Citation>Moldovan I, Katsaros E, Carr FN, et al. . The patient reported outcomes in lupus (PATROL) study: role of depression in health-related quality of life in a Southern California lupus cohort. Lupus 2011;20:1285&#x2013;92. 10.1177/0961203311412097</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203311412097</ArticleId><ArticleId IdType="pubmed">21813589</ArticleId></ArticleIdList></Reference><Reference><Citation>Thanou A, Chakravarty E, James JA, et al. . Which outcome measures in SLE clinical trials best reflect medical judgment? Lupus Sci Med 2014;1:e000005. 10.1136/lupus-2013-000005</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2013-000005</ArticleId><ArticleId IdType="pmc">PMC4225744</ArticleId><ArticleId IdType="pubmed">25396057</ArticleId></ArticleIdList></Reference><Reference><Citation>Thanou A, Merrill JT. Top 10 things to know about lupus activity measures. Curr Rheumatol Rep 2013;15:334. 10.1007/s11926-013-0334-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-013-0334-2</ArticleId><ArticleId IdType="pubmed">23606072</ArticleId></ArticleIdList></Reference><Reference><Citation>Guaracha-Bas&#xe1;&#xf1;ez GA, Contreras-Y&#xe1;&#xf1;ez I, Hern&#xe1;ndez-Molina G, et al. . Clinical and Bioethical implications of health care interruption during the COVID-19 pandemic: a cross-sectional study in outpatients with rheumatic diseases. PLOS ONE 2021;16:e0253718. 10.1371/journal.pone.0253718</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0253718</ArticleId><ArticleId IdType="pmc">PMC8270122</ArticleId><ArticleId IdType="pubmed">34242245</ArticleId></ArticleIdList></Reference><Reference><Citation>McDermott MM, Newman AB. Preserving clinical trial integrity during the coronavirus pandemic. JAMA 2020;323:2135&#x2013;6. 10.1001/jama.2020.4689</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.4689</ArticleId><ArticleId IdType="pubmed">32211830</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang W, Inzerillo S, Weiner J, et al. . The impact of telemedicine on rheumatology care. Front Med (Lausanne) 2022;9:876835. 10.3389/fmed.2022.876835</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.876835</ArticleId><ArticleId IdType="pmc">PMC9163385</ArticleId><ArticleId IdType="pubmed">35669922</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang W, Khalili L, Askanase A. Telerheumatology: a narrative review. Rheumatol Immunol Res 2021;2:139&#x2013;45. 10.2478/rir-2021-0020</Citation><ArticleIdList><ArticleId IdType="doi">10.2478/rir-2021-0020</ArticleId><ArticleId IdType="pmc">PMC9524794</ArticleId><ArticleId IdType="pubmed">36465071</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson LE, Edgil TA, Hill B, et al. . Telemedicine in rheumatology care: a systematic review. Semin Arthritis Rheum 2022;56:152045. 10.1016/j.semarthrit.2022.152045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2022.152045</ArticleId><ArticleId IdType="pubmed">35843158</ArticleId></ArticleIdList></Reference><Reference><Citation>de Thurah A, Stengaard-Pedersen K, Axelsen M, et al. . Tele-health followup strategy for tight control of disease activity in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2018;70:353&#x2013;60. 10.1002/acr.23280</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23280</ArticleId><ArticleId IdType="pubmed">28511288</ArticleId></ArticleIdList></Reference><Reference><Citation>So H, Chow E, Cheng IT, et al. . Use of Telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak: the 6-month results of a randomized controlled trial. Lupus 2022;31:488&#x2013;94. 10.1177/09612033221084515</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221084515</ArticleId><ArticleId IdType="pmc">PMC8902321</ArticleId><ArticleId IdType="pubmed">35254169</ArticleId></ArticleIdList></Reference><Reference><Citation>Piga M, Floris A, Congia M, et al. . Telemedicine in rheumatology: high specificity and sensitivity of follow-up virtual Video consultations during COVID-19 pandemic. Rheumatology 2022;61:1795&#x2013;801. 10.1093/rheumatology/keab632</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab632</ArticleId><ArticleId IdType="pmc">PMC8436393</ArticleId><ArticleId IdType="pubmed">34352098</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Urowitz MB, Goldsmith CH, et al. . The reliability of the systemic lupus International collaborating clinics/American college of rheumatology damage index in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:809&#x2013;13. 10.1002/art.1780400506</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400506</ArticleId><ArticleId IdType="pubmed">9153540</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoll T, Seifert B, Isenberg DA. SLICC/ACR damage index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 1996;35:248&#x2013;54. 10.1093/rheumatology/35.3.248</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/35.3.248</ArticleId><ArticleId IdType="pubmed">8620300</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin LI. A Concordance correlation coefficient to evaluate reproducibility. Biometrics 1989;45:255&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">2720055</ArticleId></ArticleIdList></Reference><Reference><Citation>Isenberg DA, Allen E, Farewell V, et al. . An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. Ann Rheum Dis 2011;70:54&#x2013;9. 10.1136/ard.2010.132068</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2010.132068</ArticleId><ArticleId IdType="pubmed">20833737</ArticleId></ArticleIdList></Reference><Reference><Citation>Radner H, Grisar J, Smolen JS, et al. . Value of self-performed joint counts in rheumatoid arthritis patients near remission. Arthritis Res Ther 2012;14:R61. 10.1186/ar3777</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar3777</ArticleId><ArticleId IdType="pmc">PMC3446429</ArticleId><ArticleId IdType="pubmed">22417647</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung PP, Gossec L, Mak A, et al. . Reliability of joint count assessment in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum 2014;43:721&#x2013;9. 10.1016/j.semarthrit.2013.11.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2013.11.003</ArticleId><ArticleId IdType="pubmed">24332117</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriens C, Aberle T, Carthen F, et al. . Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers. Lupus Sci Med 2020;7:e000360. 10.1136/lupus-2019-000360</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2019-000360</ArticleId><ArticleId IdType="pmc">PMC7073780</ArticleId><ArticleId IdType="pubmed">32201595</ArticleId></ArticleIdList></Reference><Reference><Citation>Tani C, Trieste L, Lorenzoni V, et al. . Health information technologies in systemic lupus erythematosus: focus on patient assessment. Clin Exp Rheumatol 2016;34:S54&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">27762204</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven RF, Mosca M, Bertsias G, et al. . Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 2014;73:958&#x2013;67. 10.1136/annrheumdis-2013-205139</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-205139</ArticleId><ArticleId IdType="pubmed">24739325</ArticleId></ArticleIdList></Reference><Reference><Citation>McElhone K, Abbott J, Shelmerdine J, et al. . Development and validation of a disease-specific health-related quality of life measure, the Lupusqol, for adults with systemic lupus erythematosus. Arthritis Rheum 2007;57:972&#x2013;9. 10.1002/art.22881</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22881</ArticleId><ArticleId IdType="pubmed">17665467</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe F, Clauw DJ, Fitzcharles M-A, et al. . Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. J Rheumatol 2011;38:1113&#x2013;22. 10.3899/jrheum.100594</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.100594</ArticleId><ArticleId IdType="pubmed">21285161</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster K, Cella D, Yost K. The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 2003;1:79. 10.1186/1477-7525-1-79</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1477-7525-1-79</ArticleId><ArticleId IdType="pmc">PMC317391</ArticleId><ArticleId IdType="pubmed">14678568</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. J Gen Intern Med 2001;16:606&#x2013;13. 10.1046/j.1525-1497.2001.016009606.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1525-1497.2001.016009606.x</ArticleId><ArticleId IdType="pmc">PMC1495268</ArticleId><ArticleId IdType="pubmed">11556941</ArticleId></ArticleIdList></Reference><Reference><Citation>Askanase AD, Daly RP, Okado M, et al. . Development and content validity of the lupus foundation of America rapid evaluation of activity in lupus (LFA-REAL&#x2122;): a patient-reported outcome measure for lupus disease activity. Health Qual Life Outcomes 2019;17:99. 10.1186/s12955-019-1151-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12955-019-1151-8</ArticleId><ArticleId IdType="pmc">PMC6555910</ArticleId><ArticleId IdType="pubmed">31174541</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikiphorou E, Radner H, Chatzidionysiou K, et al. . Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. Arthritis Res Ther 2016;18. 10.1186/s13075-016-1151-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-016-1151-6</ArticleId><ArticleId IdType="pmc">PMC5086038</ArticleId><ArticleId IdType="pubmed">27793211</ArticleId></ArticleIdList></Reference><Reference><Citation>Rampakakis E, Ste-Marie PA, Sampalis JS, et al. . Real-life assessment of the validity of patient global impression of change in fibromyalgia. RMD Open 2015;1:e000146. 10.1136/rmdopen-2015-000146</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2015-000146</ArticleId><ArticleId IdType="pmc">PMC4623367</ArticleId><ArticleId IdType="pubmed">26535150</ArticleId></ArticleIdList></Reference><Reference><Citation>Bombardier C, Gladman DD, Urowitz MB, et al. . Derivation of the Sledai. A disease activity index for lupus patients. Arthritis Rheum 1992;35:630&#x2013;40. 10.1002/art.1780350606</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780350606</ArticleId><ArticleId IdType="pubmed">1599520</ArticleId></ArticleIdList></Reference><Reference><Citation>Thanou A, Chakravarty E, James JA, et al. . How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index. Rheumatology (Oxford) 2014;53:2175&#x2013;81. 10.1093/rheumatology/keu153</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keu153</ArticleId><ArticleId IdType="pmc">PMC4542656</ArticleId><ArticleId IdType="pubmed">24729400</ArticleId></ArticleIdList></Reference><Reference><Citation>Yee C-S, Farewell V, Isenberg DA, et al. . Revised British isles lupus assessment group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. Arthritis Rheum 2006;54:3300&#x2013;5. 10.1002/art.22162</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22162</ArticleId><ArticleId IdType="pubmed">17009266</ArticleId></ArticleIdList></Reference><Reference><Citation>Yee C-S, Farewell V, Isenberg DA, et al. . British isles lupus assessment group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 2007;56:4113&#x2013;9. 10.1002/art.23130</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.23130</ArticleId><ArticleId IdType="pmc">PMC2659367</ArticleId><ArticleId IdType="pubmed">18050213</ArticleId></ArticleIdList></Reference><Reference><Citation>Askanase A, Li X, Pong A, et al. . Preliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instruments. Lupus Sci Med 2015;2:e000075. 10.1136/lupus-2014-000075</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2014-000075</ArticleId><ArticleId IdType="pmc">PMC4378376</ArticleId><ArticleId IdType="pubmed">25861457</ArticleId></ArticleIdList></Reference><Reference><Citation>Buyon JP, Petri MA, Kim MY, et al. . The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005;142:953&#x2013;62. 10.7326/0003-4819-142-12_part_1-200506210-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-142-12_part_1-200506210-00004</ArticleId><ArticleId IdType="pubmed">15968009</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Kim MY, Kalunian KC, et al. . Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550&#x2013;8. 10.1056/NEJMoa051135</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa051135</ArticleId><ArticleId IdType="pubmed">16354891</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonilla-Martinez ZL, Albrecht J, Troxel AB, et al. . The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus. Arch Dermatol 2008;144:173&#x2013;80. 10.1001/archderm.144.2.173</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archderm.144.2.173</ArticleId><ArticleId IdType="pmc">PMC2829653</ArticleId><ArticleId IdType="pubmed">18283174</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakka S, Krain RL, Concha JSS, et al. . The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review. Ann Transl Med 2021;9:431. 10.21037/atm-20-5048</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm-20-5048</ArticleId><ArticleId IdType="pmc">PMC8033342</ArticleId><ArticleId IdType="pubmed">33842652</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokka T, Pincus T. Quantitative joint assessment in rheumatoid arthritis. Clin Exp Rheumatol 2005;23:S58&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">16273786</ArticleId></ArticleIdList></Reference><Reference><Citation>Benziger CP, Huffman MD, Sweis RN, et al. . The telehealth ten: a guide for a patient-assisted virtual physical examination. Am J Med 2021;134:48&#x2013;51. 10.1016/j.amjmed.2020.06.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2020.06.015</ArticleId><ArticleId IdType="pmc">PMC7368154</ArticleId><ArticleId IdType="pubmed">32687813</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>